Boustead Singapore invests in robotic urological diagnostics with the acquisition of UroMedTech
The Southeast Asian engineering giant Boustead Singapore has acquired 60% of UroMedTech, a developer of robotic technologies for prostate cancer diagnosis. The operation marks the company's strategic entry into the medical robotics sector, where additive manufacturing and engineering precision converge to meet growing clinical needs.
The acquisition, announced on 3 July 2026, will provide UroMedTech with the capital needed to accelerate product development and international expansion. For Boustead, it represents a growth opportunity in one of the fastest-expanding healthcare markets.
A growing market fueled by early diagnosis
Prostate cancer represents an expanding global health challenge, with rising diagnosis rates but declining mortality thanks to early detection.
In 2022, nearly 1.5 million people worldwide were diagnosed with prostate cancer. Estimates indicate that one in eight men will receive this diagnosis in their lifetime.
At the same time, mortality rates have begun to decline. This is mainly due to early diagnosis, which enables timely and more effective interventions.
- Boustead Singapore acquires 60% of UroMedTech for 60 million Singapore dollars
- UroMaster is a robotic platform to improve precision and consistency in prostate cancer diagnosis
- 1.5 million global diagnoses in 2022, with one in eight men affected in their lifetime
- Additive manufacturing supports the development of personalized robotic medical devices
UroMaster: robotics for diagnostic precision
UroMedTech's robotic platform aims to standardize urological diagnostic procedures, reducing operator-dependent variability.
UroMaster is designed to improve prostate cancer diagnosis through greater procedural precision and consistency. The robotic platform assists physicians in early detection, supporting the trend of reducing mortality.
Although UroMaster is primarily a robotic diagnostic system, its development reflects broader industry trends. The convergence of robotics, artificial intelligence, and digital manufacturing is redefining how medical devices are designed and produced.
The role of 3D printing in medical robotics
Additive manufacturing emerges as an enabling technology for the production of customized robotic components and rapid prototypes in the medical sector.
The development of UroMaster illustrates how 3D printing supports the medical robotics industry. Although the platform itself is a robotic system, additive manufacturing technologies play a crucial role in the development process.
3D printing enables rapid prototyping of complex components. It also allows the customization of surgical and diagnostic instruments based on the specific anatomical needs of patients.
Additive manufacturing in the medical sector is not limited to the production of final devices, but supports the entire development cycle: from rapid prototyping to clinical validation, up to the production of customized components.
Boustead: from traditional engineering to health technology
The acquisition represents a strategic diversification for Boustead, which applies its precision engineering expertise to a high-growth-potential sector.
Boustead Singapore is recognized as one of the leading engineering and infrastructure companies in Southeast Asia. It traditionally operates in energy engineering, real estate solutions, and geospatial technologies.
The investment in UroMedTech marks the entry of health technology as a strategic long-term growth area. The acquisition adds a high-potential medical robotics company to Boustead's technology portfolio.
The move reflects a broader shift in advanced manufacturing. Companies with precision engineering expertise are increasingly applying these capabilities to the healthcare sector.
Outlook for the Asian market
Singapore positions itself as a hub for innovation in medical robotics, attracting investments in technologies that combine digital manufacturing and clinical applications.
The acquisition takes place in a favorable context for Singapore. The country is developing a robust ecosystem for advanced medical technologies, with government support and research infrastructure.
For UroMedTech, Boustead's support means access to established commercial networks and resources for international expansion. The company will be able to accelerate the commercialization of UroMaster in Asian markets and beyond.
The convergence of robotics, 3D printing, and artificial intelligence in the medical sector promises to transform not only urological diagnostics but the entire landscape of precision medical devices.
article written with the help of artificial intelligence systems
Q&A
What percentage of UroMedTech did Boustead Singapore acquire?
Boustead Singapore acquired 60% of UroMedTech. The transaction was valued at 60 million Singapore dollars.
What is the main purpose of the UroMaster robotic platform?
UroMaster is designed to improve precision and consistency in prostate cancer diagnosis. The system aims to reduce operator-dependent variability in urological procedures.
How many prostate cancer diagnoses were recorded globally in 2022?
In 2022, nearly 1.5 million people worldwide received a prostate cancer diagnosis. Estimates indicate that one in eight men will receive this diagnosis in their lifetime.
How does early diagnosis contribute to mortality rates?
Prostate cancer mortality rates are declining thanks to early detection. Early diagnosis indeed enables more timely and effective medical interventions.
What role does additive manufacturing play in the development of UroMaster?
Additive manufacturing supports the development of customized robotic medical devices and rapid prototypes. This enabling technology converges with robotics to redefine the production of medical components.
